alexa
Reach Us +441730450007
Editor - Betty Tyler | sample | 16265
ISSN: 2329-6895

Journal of Neurological Disorders
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Betty Tyler

Betty Tyler
Betty Tyler
Department of Neurosurgery
Johns Hopkins University
Hunterian Brain Tumor Laboratory
USA

Biography

Dr. Betty Tyler is an Assistant Professor of Neurosurgery at Johns Hopkins University. She runs a highly successful and productive laboratory and has a national reputation for stellar science in the field of translational research and local delivery of chemotherapeutic agents for brain tumor therapy. Betty assisted in the preclinical studies that led to bringing Gliadel to brain tumor patients as a standard of care, and currently the focus of Betty’s work and primary funding has been to develop and take a second locally delivered chemotherapeutic agent to clinical trials. Betty’s collaborative efforts with scientists within Johns Hopkins as well as with researchers throughout the United States have led to multiple scientific breakthroughs. In addition to publishing over 85 peer-reviewed articles she has mentored and taught over 250 neurosurgical residents, medical students, and undergraduate students in research design, surgical techniques and statistical analysis.

Research Interest

Dr. Betty is a successful and productive scientist who directs a neurosurgical laboratory at Johns Hopkins University, and has a national reputation for stellar science in the field of translational research and local delivery of chemotherapeutic agents for brain tumor therapy. Betty assisted in the preclinical studies that led to bringing Gliadel to brain tumor patients as a standard of care, and Betty also evaluated the efficacy of the local delivery of Paclitaxel from a novel thermal gel depot through commercial funding. The data in these studies was the scientific basis of a multi-institutional Phase I clinical trial for patients with malignant glioma. Currently the focus of her work and primary funding has been to develop and take another locally delivered chemotherapeutic agent to clinical trials. Betty’s extensive body of work with preclinical brain tumor models has resulted in her success in obtaining funding for her laboratory. She has worked on microchip delivery systems for brain tumor therapy. She directs her work towards therapeutic progress, and mentoring the next generation of scientists. She is particularly interested in bringing promising new therapies to patients with brain tumors and making a difference in the brain cancer research field.

Certificate

Certificate

Global Speakers in the subject

Global Experts in the subject

Relevant Topics
Top